12/27
08:11 am
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "neutral" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $0.25 price target on the stock, down previously from $3.50.
High
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "neutral" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $0.25 price target on the stock, down previously from $3.50.
12/27
08:11 am
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "neutral" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $0.25 price target on the stock, down previously from $3.50.
High
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "neutral" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $0.25 price target on the stock, down previously from $3.50.
12/27
07:31 am
virx
Rating for VIRX
High
Report
Rating for VIRX
12/27
06:59 am
virx
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
High
Report
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
12/27
06:59 am
virx
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
High
Report
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
11/14
12:07 pm
virx
Rating for VIRX
Low
Report
Rating for VIRX
11/14
12:07 pm
virx
Rating for VIRX
Low
Report
Rating for VIRX